Roche's Alecensa latest beneficiary of faster China drug approvals

Roche's Alecensa latest beneficiary of faster China drug approvals
FILE PHOTO: Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration/File Photo Copyright Dado Ruvic(Reuters)
By Reuters
Share this articleComments
Share this articleClose Button

ZURICH (Reuters) - Chinese regulators are speeding up drug approvals, with Roche's <ROG.S> Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.

China's National Drug Administration backed the Swiss drugmaker's Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals.

(Reporting by John Miller)

Share this articleComments

You might also like